IADC

Boston Drug and Device Litigator Moves to Shook

Retrieved on: 
Thursday, February 29, 2024

BOSTON, Feb. 29, 2024 /PRNewswire/ -- Shook, Hardy & Bacon welcomes drug and device litigator Lisa Oliver White to the firm as partner.

Key Points: 
  • BOSTON, Feb. 29, 2024 /PRNewswire/ -- Shook, Hardy & Bacon welcomes drug and device litigator Lisa Oliver White to the firm as partner.
  • White will join Shook's world renowned Product Liability Litigation Practice and focus primarily on drug and device litigation.
  • "We're excited to bring Lisa to Shook," said Trial Partner Hildy Sastre from Miami, co-chair of the firm's product liability litigation team.
  • With White on board, Shook looks forward to expanding its presence in the drug and device space in the Boston market.

MUSICK PEELER & GARRETT PARTNER LISA HSIAO NAMED ORANGE COUNTY VISIONARY

Retrieved on: 
Friday, October 20, 2023

LOS ANGELES, Oct. 20, 2023 /PRNewswire/ -- Musick, Peeler & Garett LLP announced today that Lisa Hsiao has been recognized by the Los Angeles Times as an " Orange County Visionary. "

Key Points: 
  • LOS ANGELES, Oct. 20, 2023 /PRNewswire/ -- Musick, Peeler & Garett LLP announced today that Lisa Hsiao has been recognized by the Los Angeles Times as an " Orange County Visionary. "
  • The professionals profiled in this publication "exemplify exceptional leadership qualities within their industries and organizations, while making a significant impact on communities in Orange County," states the publisher.
  • "This accomplishment speaks volumes about Lisa's legal prowess, commitment to excellence, and unwavering dedication to our community," says Managing Partner R. Joseph De Briyn.
  • Within the firm, Hsiao's leadership extends to co-leading the Business Litigation Insurance Defense Group and actively participating in the Technology and Recruiting Committees.

SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology

Retrieved on: 
Monday, October 16, 2023

SOTIO will leverage Synaffix’s ADC technology platform to develop up to three novel ADCs targeting distinct tumor-associated antigens.

Key Points: 
  • SOTIO will leverage Synaffix’s ADC technology platform to develop up to three novel ADCs targeting distinct tumor-associated antigens.
  • In addition to GlycoConnect™ and HydraSpace™, the deal also includes Synaffix’s potent linker-payload platform including multiple different payloads.
  • “Synaffix’s ADC technology perfectly complements the technologies already in SOTIO’s ADC platform, including the iADC technology licensed from NBE-Therapeutics and the ConjuALL technology licensed from LegoChem,” said Martin Steegmaier, chief scientific officer of SOTIO.
  • SOTIO additionally has two other ADC programs in preclinical development.

Siemens AG and Paessler AG strengthen their partnership in industrial environments

Retrieved on: 
Thursday, May 25, 2023

CHICAGO, May 25, 2023 /PRNewswire/ -- Siemens and Paessler announce that Paessler PRTG monitoring software will be used as the monitoring solution of the Siemens Lifecycle Management Suite (LMS).

Key Points: 
  • At the Hannover Fair in Germany, Siemens and Paessler strengthened their association in the industrial space with the confirmation that Paessler PRTG is an essential part of Siemens' Lifecycle Management Suite (LMS).
  • This development builds on the partnership between Siemens and Paessler.
  • PRTG is already used with Siemens' Industrial Automation DataCenter (IADC), which can be maintained by LMS.
  • Helmut Binder, CEO of Paessler, highly values the ongoing trust that Siemens has shown in Paessler PRTG monitoring software.

Global 'Rules of the Road' Included in Landmark Update to Space Safety Best Practices

Retrieved on: 
Tuesday, April 4, 2023

The Space Safety Coalition (SSC) published an enhanced version of its "Best Practices for the Sustainability of Space Operations" (SSC Best Practices) document to address emerging safety and sustainability concerns more proactively in the space environment.

Key Points: 
  • The Space Safety Coalition (SSC) published an enhanced version of its "Best Practices for the Sustainability of Space Operations" (SSC Best Practices) document to address emerging safety and sustainability concerns more proactively in the space environment.
  • The practices provide a model framework of topics that are critical to address for space safety.
  • "Best practices spanning all phases of the spacecraft life cycle must keep pace as our use of and reliance upon space ever deepens."
  • Founded in 2019, the SSC was established to evolve, maintain, and promote a set of best practices for safe space operations.

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Retrieved on: 
Thursday, March 30, 2023

SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2022, its recent business highlights, and a preview of select anticipated milestones.

Key Points: 
  • The safety profile is generally consistent with prior data; asymptomatic neutropenia was the primary adverse event and no new safety signals were observed.
  • Additional Pipeline Programs: A Sutro Research Forum, held in 2022, highlighted STRO-003 and Sutro’s emerging research portfolio.
  • Sutro bolstered the Senior Management Team with the promotion of Brunilda Shtylla to Chief Business Officer, who leads Business Development.
  • Total operating expenses for the year ended December 31, 2022 were $196.7 million, as compared to $160.4 million for the same period in 2021.

Sutro Biopharma to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 23, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.
  • The presentations will be accessible through the News & Events page of the Investor Relations section of the companys website at www.sutrobio.com .
  • Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs).
  • Follow Sutro on Twitter,@Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Thursday, November 3, 2022

Soheil Meshinchi, M.D., Ph.D., Principal Investigator for the compassionate use program with STRO-002 in relapsed/refractory CBF2AT3-GLIS2 AML, will deliver the oral presentation at 10:45 a.m. CST on December 10, 2022.

Key Points: 
  • Soheil Meshinchi, M.D., Ph.D., Principal Investigator for the compassionate use program with STRO-002 in relapsed/refractory CBF2AT3-GLIS2 AML, will deliver the oral presentation at 10:45 a.m. CST on December 10, 2022.
  • Following the conference, the presentation materials will be available in the Clinical/Scientific Presentation and Publication Highlights section of Sutro Biopharmas website at www.sutrobio.com .
  • Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs).
  • Follow Sutro on Twitter,@Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Sutro Biopharma to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 2, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.
  • The presentations will be accessible through the News & Events page of the Investor Relations section of the companys website at www.sutrobio.com .
  • Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs).
  • Follow Sutro on Twitter,@Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Sutro Biopharma Announces Departure of Chief Medical Officer

Retrieved on: 
Monday, October 24, 2022

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Chief Medical Officer, Arturo Molina, M.D., M.S., F.A.C.P.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Chief Medical Officer, Arturo Molina, M.D., M.S., F.A.C.P.
  • We thank Arturo for his many contributions to the Company and wish him well as he pursues his future endeavors, said Bill Newell, Sutros Chief Executive Officer.
  • Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs).
  • Follow Sutro on Twitter,@Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.